Skip to main content
Ascletis Pharma Inc. logo

Ascletis Pharma Inc. — Investor Relations & Filings

Ticker · 1672 ISIN · KYG0520K1094 LEI · 254900SKEFCO9I3GPL05 HKEX Manufacturing
Open in API
Filings indexed 1,474 across all filing types
Latest filing 2020-09-01 Share Issue/Capital Cha…
Country KY Cayman Islands
Listing HKEX 1672

About Ascletis Pharma Inc.

http://www.ascletis.com

Ascletis Pharma Inc. is a fully integrated, R&D driven biotechnology company dedicated to the development and commercialization of potential best-in-class and first-in-class therapeutics. The company covers the entire value chain from discovery to sales. Ascletis primarily focuses on metabolic diseases, including chronic weight management, utilizing proprietary platforms such as Artificial Intelligence-assisted Structure-Based Drug Discovery (AISBDD), Ultra-Long-Acting Platform (ULAP), and Peptide Oral Transport ENhancement Technology (POTENT). Key pipeline candidates include ASC30 (oral/subcutaneous GLP-1R agonist), ASC35 (GLP-1R/GIPR dual agonist), ASC36 (amylin receptor agonist), and ASC37 (GLP-1R/GIPR/GCGR triple agonist). The company also maintains active programs in viral diseases, NASH/PBC, and oncology.

Recent filings

Filing Released Lang Actions
Monthly Return of Equity Issuer on movements in Securities for the month ended 31 August 2020
Share Issue/Capital Change Classification · 95% confidence The document is titled 'Monthly Return of Equity Issuer on Movements in Securities' for the month ended 31/8/2020, submitted to the Hong Kong Exchanges and Clearing Limited. It details movements in authorised share capital, issued share capital, share options, warrants, convertibles, and other share capital changes. The content is focused on share capital changes and movements during a specific month, which aligns with disclosures about share capital changes rather than a full financial report or earnings release. It is not an announcement of a report publication but a detailed monthly regulatory filing about share capital movements. This fits the definition of a Share Issue/Capital Change (SHA) filing, which covers announcements regarding new share issues, stock splits, or other capital changes. The document length (13,340 characters) and detailed tables support it being a substantive filing rather than a brief announcement or certification. Therefore, the correct classification is SHA with high confidence.
2020-09-01 English
INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2020
Interim / Quarterly Report Classification · 95% confidence The document is titled 'INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2020' and contains detailed unaudited condensed consolidated interim financial results, including revenue, gross profit, loss before tax, and loss for the period. It also includes a management discussion and analysis section reviewing business progress, product pipeline, and clinical trial updates. The document length is about 15,000 characters, indicating it is a substantive report rather than a brief announcement. The content focuses on financial performance and operational updates for a six-month period, which aligns with an Interim / Quarterly Report. There is no indication that this is merely an announcement of a report or a certification letter, so it should not be classified as RPA or RNS. Therefore, the appropriate classification is Interim / Quarterly Report (IR). H1 2020
2020-08-28 English
ANNOUNCEMENT OF INTERIM RESULTS 2020
Interim / Quarterly Report Classification · 100% confidence The document is titled 'ANNOUNCEMENT OF INTERIM RESULTS 2020' and contains detailed unaudited consolidated interim financial statements for the six months ended 30 June 2020, including profit and loss, financial position, segment information, notes on accounting policies, and taxation. The presence of comprehensive financial data and analysis for a half-year period aligns with the characteristics of an Interim / Quarterly Report. The document is about 15,000 characters long, indicating it is a full report rather than a brief announcement or certification. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). H1 2020
2020-08-25 English
VOLUNTARY ANNOUNCEMENT - COMPLETION OF BRIDGING STUDY OF ASC18
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by Ascletis Pharma Inc. regarding the completion of a bridging study of a drug candidate ASC18. It provides details about the study design, results, and related clinical trial outcomes. The document is relatively short (2957 characters) and does not contain financial statements, regulatory certifications, or detailed financial data. It is an announcement of a scientific/clinical milestone rather than a financial report or regulatory filing. There is no indication that this is an Annual Report, Interim Report, Earnings Release, or any other financial or governance report. It is also not a regulatory filing or certification. Given the content and length, this fits best as a Regulatory Filing (RNS) since it is a general announcement that does not fit other specific categories.
2020-08-20 English
VOLUNTARY ANNOUNCEMENT - FIRST HBV PATIENT DOSED IN PHASE IIa CLINICAL TRIAL OF ASC22, A SUBCUTANEOUSLY ADMINISTERED PD-L1 ANTIBODY
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by Ascletis Pharma Inc. regarding the dosing of the first patient in a Phase IIa clinical trial for a drug candidate (ASC22). It contains no financial data, no regulatory filings, no voting results, no management changes, no earnings or annual report information. The document is short (2394 characters) and is an announcement of a clinical trial milestone, not a financial or regulatory report. It does not fit into categories like Annual Report, Earnings Release, or Regulatory Filings. It is a voluntary announcement about a clinical trial progress, which is best categorized under Regulatory Filings (RNS) as a general announcement that does not fit other specific categories.
2020-08-17 English
DATE OF BOARD MEETING
Regulatory Filings Classification · 95% confidence The document is an announcement from the board of directors of World Houseware (Holdings) Limited about the date of a board meeting. The meeting will approve the release of the unaudited interim results for the six months ended 30 June 2020 and consider the payment of an interim dividend. The document does not contain the actual interim financial results or detailed financial data, but rather announces the upcoming board meeting where these results will be approved and released. The document length is short (1668 characters) and it is clearly an announcement of a meeting and forthcoming report release, not the report itself. Therefore, it fits the category of a Regulatory Filing (RNS) as a general regulatory announcement about the board meeting and report release, rather than an Interim Report (IR) or Earnings Release (ER).
2020-08-13 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.